Директен банков превод Western Union, Moneygram
Scapho 150mg is a Subcutaneous IgG1 monoclonal antibody which prevents interleukin-17A (IL-17A) by binding to its receptor; maintenance dose given once monthly
Used for curing adults with moderate to severe plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis; in PsA, the drug slows progression of joint damage
May have high risk for severe infection and may leads to hypersensitivity reactions
Scapho 150mg indicated for the treatment of patients with following condition;
Starting dose: given 300 mg SC at weeks 0, 1, 2, 3, and 4
initially at week 8, administer 300 mg SC once monthly
The recommended dose of 150 mg may be acceptable for some patients
Indicated for adults with active psoriatic arthritis
Psoriatic arthritis for other patients, administer with or without a loading dosage by SC injection
Scapho with loading dose administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter
Scapho without loading dose administrated 150 mg SC q4wk.
Consider a dosage of 300 mg, If a patient continues to have active psoriatic arthritis
May be administered with or without methotrexate.
Given with or without a loading dosage by SC injection
Scapho with loading dose is administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter
Scapho without a loading dose is administrated150 mg SC q4wk
Secukinumab belongs to human IgG1 monoclonal antibody whichspecially binds to the interleukin-17A (IL-17A) cytokine, preventing its combining with the IL-17 receptor. A naturally occurring cytokine, IL-17A is contains in normal inflammatory and immune responses. IL-17A activates keratinocytes to secrete chemokines and other proinflammatory cells. Increase concentrations of IL-17A are found in psoriatic plaques. Secukinumab treatmentprohibits the release of proinflammatory cytokines and chemokines and may decrease epidermal neutrophils and IL-17A concentrations in psoriatic plaques.
Absorption: peak plasma concentration for single dose is 6 days and weekly dosing for first month is 31-34 days
Distribution: volume of distribution is 7.1 – 8.6 (IV administration)
Metabolism: Metabolized via intracellular catabolism
Elimination: half-life is 22-31 days
CYP450 substrates interaction with scapho injection may altered by increased levels of certain cytokines
Live vaccinations interaction with scapho should be avoided
Patients having Serious hypersensitivity reactions to the active substance or to any of the excipients
Pregnancy category is B
Use the Scapho 150mg with caution during pregnancy
Excretion into human milk is unknown
Store the drug at 20C – 80C
Store in original carton and protect from light until the time of use
If missed dose occurs, patients must consult with medical practitioner and follow the instructions given by them.
Or missed dose should be avoid and follow the regular dosing schedule.
Check out the stock offers. It's nice to save!Покажи всички